Journal
MOLECULES
Volume 28, Issue 18, Pages -Publisher
MDPI
DOI: 10.3390/molecules28186546
Keywords
drug-target interactions; graph convolutional network; graph attention network; representation learning; machine learning
Ask authors/readers for more resources
BG-DTI is a learning-based framework for predicting drug-target interactions. It combines approaches based on biological features and heterogeneous networks and utilizes a graph representation learning module to learn the features representation of drugs and targets. The fusion descriptors obtained from the module are fed into a random forest classifier for DTI prediction. Evaluation results demonstrate that BG-DTI outperforms other methods.
The prediction of drug-target interaction (DTI) is crucial to drug discovery. Although the interactions between the drug and target can be accurately verified by traditional biochemical experiments, the determination of DTI through biochemical experiments is a time-consuming, laborious, and expensive process. Therefore, we propose a learning-based framework named BG-DTI for drug-target interaction prediction. Our model combines two main approaches based on biological features and heterogeneous networks to identify interactions between drugs and targets. First, we extract original features from the sequence to encode each drug and target. Later, we further consider the relationships among various biological entities by constructing drug-drug similarity networks and target-target similarity networks. Furthermore, a graph convolutional network and a graph attention network in the graph representation learning module help us learn the features representation of drugs and targets. After obtaining the features from graph representation learning modules, these features are combined into fusion descriptors for drug-target pairs. Finally, we send the fusion descriptors and labels to a random forest classifier for predicting DTI. The evaluation results show that BG-DTI achieves an average AUC of 0.938 and an average AUPR of 0.930, which is better than those of five existing state-of-the-art methods. We believe that BG-DTI can facilitate the development of drug discovery or drug repurposing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available